Serina Therapeutics, Inc. (NYSEAMERICAN:SER) Shares Shorted: Short Interest Down 52.6% in September

Serina Therapeutics, Inc. (NYSEAMERICAN:SER) was the recipient of a significant decline in short interest during the month of September. As of September 30th, there was short interest totaling 56,600 shares, a decline of 52.6% from the September 15th total of 119,360 shares. Based on an average daily volume of 121,092 shares, the short-interest ratio is currently 0.5 days. Currently, 0.3% of the shares of the company are short sold.

Wall Street Analyst Weigh In

Separately, BTIG Research reiterated a “buy” rating and issued a $8.00 price target on shares of Serina Therapeutics in a research note on Thursday, September 10th. One equities research analyst has rated the stock with a Buy rating. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $8.00.

Serina Therapeutics Stock Performance

NYSEAMERICAN SER traded up $0.04 during trading on Friday, reaching $1.82. The company’s stock had a trading volume of 3,974 shares, compared to its average volume of 1,473,872. The firm has a market capitalization of $46.35 million, a price-to-earnings ratio of -0.97 and a beta of 1.19. Serina Therapeutics has a 12 month low of $1.22 and a 12 month high of $5.29. The company has a current ratio of 6.65, a quick ratio of 6.65 and a debt-to-equity ratio of 0.16. The firm has a 50 day moving average price of $2.37 and a 200 day moving average price of $2.09.

Serina Therapeutics (NYSEAMERICAN:SER) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.55) earnings per share for the quarter.

Serina Therapeutics Company Profile

Serina Therapeutics, Inc is a clinical-stage biotechnology company developing medicines designed to provide controlled and sustained drug delivery. The company’s proprietary POZ polymer platform is intended to extend the duration of action of therapeutic compounds, potentially reducing dosing frequency and improving treatment convenience.

Serina’s lead product candidate is SER-252, also known as POZ-apomorphine, an investigational long-acting formulation of apomorphine being developed for patients with Parkinson’s disease.